<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00283985</url>
  </required_header>
  <id_info>
    <org_study_id>I05009</org_study_id>
    <nct_id>NCT00283985</nct_id>
  </id_info>
  <brief_title>Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma</brief_title>
  <official_title>Phase II Study of an Association of L-asparaginase-Methotrexate-Dexamethasone for Relapsing and/or Refractory Nasal and Nasal-type NK-T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nasal/nasal type NK-T-cell lymphoma is a rare and severe type of non-Hodgkin's lymphoma (NHL)
      more frequent in Asia than in western countries. When localised, radiotherapy seems to be the
      best treatment. When radiotherapy cannot be used because of dissemination or relapse,
      chemotherapy protocols used for other types of NHL give poor results and survival is poor.
      Recently papers from China and Japan reported the efficacy of a drug: l-asparaginase, usually
      used to treat acute lymphoblastic leukemia. In vitro a selective apoptosis of NK-cell tumours
      by l-asparaginase was shown on tumour cell lines and samples.

      The investigators propose a phase II protocol for patients with refractory or relapsing
      nasal/nasal type NK-T-cell lymphoma using a regimen combining l-asparaginase, methotrexate
      and dexamethasone. Biological studies will be conducted trying to find factors which could
      predict responses to this chemotherapy.

      Since january 2009, the study concerns all patients with nasal/nasal type NK-T-cell lymphoma
      who have not received asparaginase before.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:

        -  Determine the overall and complete response rate

      Secondary Objectives:

        -  To evaluate survival without progression

        -  To evaluate total survival.

        -  To evaluate the tolerance and the side effects of the treatment.

        -  To evaluate the duration and the mode of hospitalization of the patients treated by this
           therapeutic association.

        -  To constitute a bank of biological samples - serum, tumoral, ADN, ARN to allow
           prognostic studies implying virus EBV, p53, CD94, C-kit and asparagine synthetase gene
           in order to better understand the mechanisms of the cancerogenesis of this variety of
           cytotoxic LNH and to identify the predictive factors of response to the asparaginase.

      Sampling:

      For each patient included in the protocol, the following sampling will be carried out with
      the diagnosis:

        -  Biopsy,

        -  Medullary biopsy

        -  Medullary aspiration

        -  blood: 3 tubes of 7 ml on EDTA and 3 tubs of 7 ml with heparin

      Treatment:

      All the patients included will receive three cures separated by 3 weeks (J1, J22, J43):

        -  J1: Methotrexate 3 gr/m2

        -  J2, J4, J6 and J8: Kidrolase® 6000 u/m2

        -  J1 with J4: Dexamethasone 40 mg (20 mg if age &gt; 70 years)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of chemotherapy</measure>
    <time_frame>3 month, 6 month, 9 month, 12 month, 18 month, 24 month</time_frame>
  </primary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kidrolase</intervention_name>
    <description>6000 u/ m2 IM at J2, J4 and J6 and J8. 3 to 6 cycles.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>3 gr/m2 at J1</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40 mg/ per os at J1, J2 and J4.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erwinase</intervention_name>
    <description>In case of allergy to Kidrolase
20000 u/m2 en IM at J2, J4, J6 et J8. 3 to 6 cycles</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with relapsing/refractory T-NK/NK lymphoma:

          -  Ages 18 years and above

          -  Patients must have a diagnosis of NK-cell (or T-NK) non-Hodgkin's lymphoma, nasal or
             nasal-type.

          -  Stage I, II, III, or IV disease

          -  Creatinine less than 3 x upper limit of normal (ULN)

          -  Able to give informed consent

          -  No prior treatment with asparaginase

        Patients with T-NK/NK lymphoma (de novo patients ):

          -  Ages 18 years and above

          -  Patients must have a diagnosis of NK-cell (or T-NK) non-Hodgkin's lymphoma, nasal or
             nasal-type.

          -  Stage I, II, III, or IV disease

          -  Creatinine less than 3 x upper limit of normal (ULN)

          -  Able to give informed consent

          -  no prior chemotherapy or radiotherapy

        Exclusion Criteria:

          -  Patients who are pregnant or nursing

          -  Any factor which might limit the patient's ability to provide informed consent

          -  Liver insufficiency

          -  Evolutive thrombosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaud JACCARD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Limoges</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Département Maladies du Sang</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Annecy</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Radiothérapie, Polyclinique Bordeaux Nord</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie Clinique - Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie Clinique, CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie</name>
      <address>
        <city>Evry</city>
        <zip>91080</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble-Hématologie Clinique</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lille - Maladies du Sang</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie et de Thérapie Cellulaire - CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Lorient</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon - Hématologie Clinique</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département d'Oncologie - Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hématologie Adulte, Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département d'Immuno-Hématologie, Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Lariboisière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital St Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie Clinique, Groupe Hospitalier Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie Clinique, Groupe Hospitalier Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Immunologie Clinique 2, Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie Clinique, CHU de Reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel-Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département Hématologie Clinique</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2006</study_first_submitted>
  <study_first_submitted_qc>January 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2006</study_first_posted>
  <last_update_submitted>February 27, 2013</last_update_submitted>
  <last_update_submitted_qc>February 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NK/T-cell lymphoma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>L-asparaginase</keyword>
  <keyword>Nasal NK-cell lymphoma</keyword>
  <keyword>Nasal-type NK-cell Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

